102 related articles for article (PubMed ID: 27467708)
1. Cognitive dysfunction after withdrawal of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia.
Claudiani S; Apperley JF; Deplano S; Khorashad J; Foroni L; Palanicawandar R; Perry R; Milojkovic D
Am J Hematol; 2016 Nov; 91(11):E480-E481. PubMed ID: 27467708
[No Abstract] [Full Text] [Related]
2. Imatinib--A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015.
Gambacorti-Passerini C; Piazza R
JAMA Oncol; 2015 May; 1(2):143-4. PubMed ID: 26181011
[No Abstract] [Full Text] [Related]
3. Chronic Myelogenous Leukemia: Pregnancy in the Era of Stopping Tyrosine Kinase Inhibitor Therapy.
Berman E; Druker BJ; Burwick R
J Clin Oncol; 2018 Apr; 36(12):1250-1256. PubMed ID: 29447062
[No Abstract] [Full Text] [Related]
4. Ponatinib-induced neutrophilic panniculitis.
Zhang M; Hassan KM; Musiek A; Rosman IS
J Cutan Pathol; 2014 Jul; 41(7):597-601. PubMed ID: 24602068
[TBL] [Abstract][Full Text] [Related]
5. [Dasatinib. A novel tyrosine kinase inhibitor for the treatment of chronic myeloid leukaemia].
Bjerrum OW; Dufva IH; Stentoft J; Hasselbalch HC
Ugeskr Laeger; 2008 Jan; 170(5):331-3. PubMed ID: 18252160
[TBL] [Abstract][Full Text] [Related]
6. Treating chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
Gale RP; Goldman JM
Acta Haematol; 2013; 130(3):192-5. PubMed ID: 23774684
[No Abstract] [Full Text] [Related]
7. Cardiovascular event in chronic myeloid leukaemia treated with tyrosine kinase inhibitor: a case report.
Boo YL; Liam CCK; Lim SY; Look ML
Hong Kong Med J; 2019 Feb; 25(1):74-5. PubMed ID: 30713145
[No Abstract] [Full Text] [Related]
8. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.
Rousselot P; Charbonnier A; Cony-Makhoul P; Agape P; Nicolini FE; Varet B; Gardembas M; Etienne G; Réa D; Roy L; Escoffre-Barbe M; Guerci-Bresler A; Tulliez M; Prost S; Spentchian M; Cayuela JM; Reiffers J; Chomel JC; Turhan A; Guilhot J; Guilhot F; Mahon FX
J Clin Oncol; 2014 Feb; 32(5):424-30. PubMed ID: 24323036
[TBL] [Abstract][Full Text] [Related]
9. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
10. Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.
Jabbour E; Cortes J; Kantarjian H
Curr Opin Oncol; 2006 Nov; 18(6):578-83. PubMed ID: 16988578
[TBL] [Abstract][Full Text] [Related]
11. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
[TBL] [Abstract][Full Text] [Related]
12. Long-term molecular efficacy and safety of imatinib in a patient with chronic myeloid leukaemia after renal transplantation.
Thierry A; Dreyfus B; Bridoux F; Abou Ayache R; Milin S; Guilhot F; Touchard G
Nephrol Dial Transplant; 2007 Jun; 22(6):1791-2. PubMed ID: 17308316
[No Abstract] [Full Text] [Related]
13. Exploring the curative potential of BCR-ABL1-targeting drugs for chronic myeloid leukaemia.
Valent P
Lancet Oncol; 2010 Nov; 11(11):1010-1. PubMed ID: 20965784
[No Abstract] [Full Text] [Related]
14. Early switch to second-line tyrosine kinase inhibitor in chronic myeloid leukemia patients failing to achieve early molecular response.
Klil-Drori AJ; Yin H; Azoulay L; Harnois M; Gratton MO; Del Corpo A; Olney HJ; Delage R; Laneuville P; Mollica L; Busque L; Assouline SE;
Am J Hematol; 2017 Oct; 92(10):E602-E604. PubMed ID: 28670773
[No Abstract] [Full Text] [Related]
15. Current opinions and controversies in chronic myeloid leukaemia.
Kishore B; Marin D
Curr Opin Oncol; 2011 Nov; 23(6):659-64. PubMed ID: 21918441
[TBL] [Abstract][Full Text] [Related]
16. Outcome of pregnancy in chronic myeloid leukaemia patients treated with tyrosine kinase inhibitors: short report from a single centre.
Alizadeh H; Jaafar H; Rajnics P; Khan MI; Kajtár B
Leuk Res; 2015 Jan; 39(1):47-51. PubMed ID: 25455655
[TBL] [Abstract][Full Text] [Related]
17. Patients' perspectives on the definition of cure in chronic myeloid leukemia.
Flynn KE; Mauro MJ; George G; Hinman A; Baim A; Kota V; Larson RA; Lipton JH; Thompson JE; Wadleigh M; Atallah E
Leuk Res; 2019 May; 80():40-42. PubMed ID: 30955853
[No Abstract] [Full Text] [Related]
18. Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib.
Ernst T; Erben P; Müller MC; Paschka P; Schenk T; Hoffmann J; Kreil S; La Rosée P; Hehlmann R; Hochhaus A
Haematologica; 2008 Feb; 93(2):186-92. PubMed ID: 18223278
[TBL] [Abstract][Full Text] [Related]
19. Severe dyspnoea in a patient with chronic myelogenous leukaemia on a tyrosine kinase inhibitor.
Ustun C; Randall N; Podgaetz E; Amin K; Dincer HE
Thorax; 2015 Jul; 70(7):701-4. PubMed ID: 25935168
[No Abstract] [Full Text] [Related]
20. Sustained molecular response in chronic myeloid leukemia deep responders treated with low dose tyrosine kinase inhibitors.
Cayssials E; Tartarin F; Guilhot J; Sorel N; Chomel JC; Leleu X; Guilhot F
Leuk Lymphoma; 2018 Mar; 59(3):766-769. PubMed ID: 28792265
[No Abstract] [Full Text] [Related]
[Next] [New Search]
